180 related articles for article (PubMed ID: 9615912)
41. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
Strauss WE; Lapsley D; Gaziano JM
Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
[TBL] [Abstract][Full Text] [Related]
42. Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects.
Einarsson C; Hillebrant CG; Axelson M
Hepatology; 2001 May; 33(5):1189-93. PubMed ID: 11343248
[TBL] [Abstract][Full Text] [Related]
43. The effect of pravastatin in relation to low density lipoprotein receptor activity.
Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
[TBL] [Abstract][Full Text] [Related]
44. Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.
Koide K; Hayashi K; Horiuchi I; Kajiyama G
Biochim Biophys Acta; 1989 Sep; 1005(1):65-71. PubMed ID: 2505850
[TBL] [Abstract][Full Text] [Related]
45. Effect of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on hepatic cholesterol 7 alpha-hydroxylase, acyl-coenzyme A: cholesterol acyltransferase, and bile lipid secretion in the hamster with intact enterohepatic circulation.
Hayashi K; Noshiro M; Kurushima H; Kuga Y; Nomura S; Ohkura Y; Ohtani H; Kurokawa J; Tanaka K; Yasunobu Y
Atherosclerosis; 1994 Dec; 111(2):183-9. PubMed ID: 7718020
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs.
Tazuma S; Hatsushika S; Aihara N; Sagawa H; Yamashita G; Sasaki M; Sasaki H; Mizuno S; Tao S; Kajiyama G
Digestion; 1992; 51(3):179-84. PubMed ID: 1521718
[TBL] [Abstract][Full Text] [Related]
47. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
48. Simultaneous determination of plasma mevalonate and 7alpha-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia: convenient indices for estimating hepatic defects of cholesterol and bile acid syntheses and biliary cholesterol supersaturation.
Shoda J; Miyamoto J; Kano M; Ikegami T; Matsuzaki Y; Tanaka N; Osuga T; Miyazaki H
Hepatology; 1997 Jan; 25(1):18-26. PubMed ID: 8985259
[TBL] [Abstract][Full Text] [Related]
49. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
Hoogerbrugge-vd Linden N; de Rooy FW; Jansen H; van Blankenstein M
Gut; 1990 Mar; 31(3):348-50. PubMed ID: 2108908
[TBL] [Abstract][Full Text] [Related]
50. Hepatic cholesterol metabolism in patients with gallstones.
Salen G; Nicolau G; Shefer S; Mosbach EH
Gastroenterology; 1975 Sep; 69(3):676-84. PubMed ID: 1158085
[TBL] [Abstract][Full Text] [Related]
51. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment.
Moghadasian MH; Nguyen LB; Shefer S; Salen G; Batta AK; Frohlich JJ
Metabolism; 2001 Jun; 50(6):708-14. PubMed ID: 11398149
[TBL] [Abstract][Full Text] [Related]
52. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
[TBL] [Abstract][Full Text] [Related]
53. Phytoconstituents of an ethanolic pod extract of Prosopis cineraria triggers the inhibition of HMG-CoA reductase and the regression of atherosclerotic plaque in hypercholesterolemic rabbits.
Ram H; Jaipal N; Charan J; Kashyap P; Kumar S; Tripathi R; Singh BP; Siddaiah CN; Hashem A; Tabassum B; Abd Allah EF
Lipids Health Dis; 2020 Jan; 19(1):6. PubMed ID: 31931807
[TBL] [Abstract][Full Text] [Related]
54. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.
Pfohl M; Naoumova RP; Klass C; Knisel W; Jakober B; Risler T; Thompson GR
J Lipid Res; 1994 Nov; 35(11):1946-55. PubMed ID: 7868973
[TBL] [Abstract][Full Text] [Related]
55. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
56. SC-435, an ileal apical sodium-codependent bile acid transporter inhibitor alters mRNA levels and enzyme activities of selected genes involved in hepatic cholesterol and lipoprotein metabolism in guinea pigs.
West KL; McGrane M; Odom D; Keller B; Fernandez ML
J Nutr Biochem; 2005 Dec; 16(12):722-8. PubMed ID: 16169202
[TBL] [Abstract][Full Text] [Related]
57. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
Jacotot B; Benghozi R; Pfister P; Holmes D
Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
[TBL] [Abstract][Full Text] [Related]
58. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
Keidar S; Aviram M; Maor I; Oiknine J; Brook JG
Br J Clin Pharmacol; 1994 Dec; 38(6):513-9. PubMed ID: 7888289
[TBL] [Abstract][Full Text] [Related]
59. Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.
Hillebrant C; Nyberg B; Angelin B; Axelson M; Björkhem I; Rudling M; Einarsson C
J Intern Med; 1999 Oct; 246(4):399-407. PubMed ID: 10583711
[TBL] [Abstract][Full Text] [Related]
60. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits.
Shiomi M; Ito T
Metabolism; 1994 May; 43(5):559-64. PubMed ID: 8177044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
